You are here

Article Text

Article menu
Download PDFPDF
Clinical science
Intermediate-term outcomes of pars plana tube insertion of Aurolab aqueous drainage implant for refractory glaucoma
  1. Naresh Babu1,
  2. Girish Baliga2,
  3. Hiruni Kaushalya Wijesinghe3,
  4. George Varghese Puthuran3
  1. 1Vitreo-retinal Services, Aravind Eye Hospital, Madurai, India
  2. 2Vitreoretina, Aravind Eye Hospital, Madurai, Tamil Nadu, India
  3. 3Glaucoma, Aravind Eye Hospital, Madurai, Tamil Nadu, India
  1. Correspondence to Dr George Varghese Puthuran, Glaucoma, Aravind Eye Hospital, 625020 Madurai, India; georgeputhuran{at}gmail.com

Abstract

Purpose To report the safety and efficacy of parsplana tube insertion of Aurolab aqueous drainage implant(AADI) in patients with refractory glaucoma.

Methods Charts of patients with refractory glaucoma who underwent AADI via the parsplana route between June 2014 and June 2018with a minimum follow-up of 6 months were retrospectively reviewed. Success was defined as complete when the intraocular pressure (IOP) was ≥5 and18 mmHg or IOP reduction was >30%from baseline without antiglaucoma medication (AGM) andas qualified if requiring additional AGMs.

Results The study included 63 eyes of 63 patients with a mean age of 36.1±20.6 years and a mean follow-up of 19.7±15.7 months. Glaucoma postvitreoretinal surgery was the the most common aetiology (22 eyes, 35%). The mean IOP reduced from 36.6±10.7 mmHg to15.7±8.2 (57.1%), 15.02±7.3 (60%) and 17.2±8.5 mmHg (53%)at 6 months and 1 and 2 years, respectively. Kaplan-Meier estimates showed that the cumulative probabilities of failure were 8% (95% CI4.3% to 22.4%) at 6 months, 23% (95%CI12.8% to 38.6%) at 1 year, 30% (95%CI17.4% to 45.9%) at 18 months and 47% (95% CI13.4% to 64.9%) at the 2 years time points.Vitreous blocking tube tip was noted up to 8% of eyes on follow-up.

Conclusion Pars plana AADI insertion is a useful procedure for the control of IOP in patients with refractory glaucoma.

  • glaucoma
  • vitreous
  • intraocular pressure
  • optic nerve

http://dx.doi.org/10.1136/bjophthalmol-2019-314639

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors GVP: concept and design of the work, critical revision of content, final approval of the version to be published and accountable for all aspects of work in ensuring questions related to the accuracy or integrity of any part of work are appropriately investigated and resolved. NB: concept and design of work, critical revision of content and final approval of the version to be published. GB and HKW: data acquisition, analysis and preparation of the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Obtained.

    • Ethics approval The institutional ethics committee of Aravind Eye Hospital, Madurai (RET201200197).

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.